ADMA Biologics Inc (ADMA)
NASDAQ:ADMA
Want to see ADMA full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.19Last Year’s EPS
0.15Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed materially positive operational and financial momentum driven by ASCENIV — including strong revenue growth (+28% YoY), substantial margin expansion (71% gross margin vs 53% prior year), improved adjusted EBITDA (+24% YoY), and robust cash generation (~$58M in Q1) — alongside strategic balance sheet actions and pipeline progress (pediatric label expansion and SG-001 preclinical work). Offsetting these positives were significant near-term headwinds in the standard IG market: BIVIGAM revenue declined sharply (-54% YoY) due to distributor ordering disruption and aggressive competitor discounting (ASP erosion of ~15%–20%), elevated channel inventory and DSOs (~107 days), and withdrawal of longer-term guidance. Overall, the company appears financially resilient and operationally well-positioned, with the performance of ASCENIV and strong cash/margin metrics outweighing the transitory channel and pricing pressures in the standard IG segment.Company Guidance
Strong ASCENIV Revenue Growth
ASCENIV revenue was $97.5 million in Q1 2026, up approximately 28% year-over-year, with record end-market demand, record new patient starts, growing prescriber adoption, improved product pull-through and patient adherence. Management cites April run-rate in line with Q1 direct sales, indicating continuing momentum into Q2.
Margin Expansion and Gross Profit
Gross profit for the quarter was $80.8 million, resulting in gross margin expansion to 71% from 53% in the prior year period (an increase of ~18 percentage points), reflecting improved mix toward higher-margin ASCENIV and yield-enhanced manufacturing.
Improved Profitability (Adjusted EBITDA and Net Income)
Adjusted EBITDA was $59.7 million, up 24% year-over-year, and adjusted net income rose ~22% year-over-year to $40.7 million. GAAP net income was $45.3 million for the quarter.
Strong Operating Cash Generation and Liquidity
Generated approximately $58 million of cash from operations in Q1 2026 (greater than all of 2025), ended the quarter with $138 million of cash and cash equivalents, received $5 million proceeds from sale of 3 plasma centers, and maintained pro forma net leverage below 0.5x with ~ $100 million of additional borrowing capacity.
Balance Sheet Actions and Capital Return
Company executed accelerated stock repurchases converting ~3.6% of outstanding shares into treasury stock and retains capacity to continue opportunistic share repurchases while supporting growth initiatives.
Operational and Supply Enhancements
Completed monetization of 3 plasma centers while adding a new third-party plasma supplier, established a balanced mix of internal and third-party plasma procurement, and is using yield-enhanced manufacturing for ASCENIV production to maximize high-titer plasma utilization.
Pipeline and Regulatory Catalysts
Received pediatric label expansion approval for ASCENIV and plans pre-IND engagement for SG-001 later in 2026; SG-001 preclinical data to be presented at an upcoming conference and management estimates a potential peak market opportunity of $300M–$500M if approved.
ADMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ADMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $10.08 | $8.47 | -15.97% |
Feb 25, 2026 | $15.68 | $15.18 | -3.19% |
Nov 05, 2025 | $15.37 | $14.03 | -8.72% |
Aug 06, 2025 | $18.54 | $16.75 | -9.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ADMA Biologics Inc (ADMA) report earnings?
ADMA Biologics Inc (ADMA) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is ADMA Biologics Inc (ADMA) earnings time?
ADMA Biologics Inc (ADMA) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADMA EPS forecast?
ADMA EPS forecast for the fiscal quarter 2026 (Q2) is 0.19.